MDM2 Antagonists Counteract Drug-Induced DNA Damage

  title={MDM2 Antagonists Counteract Drug-Induced DNA Damage},
  author={A. Vilgelm and Priscilla Escalante Cobb and Kiran Malikayil and D. Flaherty and C. Andrew Johnson and D. Raman and Nabil Saleh and B. Higgins and Brandon A Vara and J. N. Johnston and Douglas B. Johnson and M. Kelley and Sheau-Chiann Chen and G. Ayers and A. Richmond},
  pages={43 - 55}
Antagonists of MDM2-p53 interaction are emerging anti-cancer drugs utilized in clinical trials for malignancies that rarely mutate p53, including melanoma. We discovered that MDM2-p53 antagonists protect DNA from drug-induced damage in melanoma cells and patient-derived xenografts. Among the tested DNA damaging drugs were various inhibitors of Aurora and Polo-like mitotic kinases, as well as traditional chemotherapy. Mitotic kinase inhibition causes mitotic slippage, DNA re-replication, and… Expand
MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21
The authors identified a shortage of p21, a protein that inhibits the cell cycle, in resistant tumors and demonstrated that it can be reversed using a pharmacological intervention, and provided a rationale for cotargeting CDK4/6 and MDM2 in melanoma. Expand
Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors.
CDK4/6i can enhance efficacy of T-cell-based therapies, such as adoptive T cell transfer or T-activating antibodies anti-OX40/anti-4-1BB, in murine breast cancer models and uncover a link between tumor metabolic vulnerabilities and anti-tumor immunity. Expand
Effect of stress-induced polyploidy on melanoma reprogramming and therapy resistance.
This review focuses on polyploidy inducers in melanoma and their effects on transcriptional reprogramming and phenotypic adaptation as well as the relevance ofpolyploid melanoma cells for therapy resistance. Expand
Development of Personalized Therapeutic Strategies by Targeting Actionable Vulnerabilities in Metastatic and Chemotherapy-Resistant Breast Cancer PDXs
Patient Derived Xenografts (PDXs) that were obtained from metastatic and therapy-resistant breast cancer samples recapitulate the wide spectrum of the disease in terms of histologic subtypes and mutational profiles, as evaluated by whole exome sequencing. Expand
The Role of the Meiotic Component in Reproduction of B-RAF-Mutated Melanoma: A Review and “Brainstorming” Session
The ectopic expression of cancer testis (CT) antigens and classic meiotic genes is characteristic and a hallmark of poor prognosis of melanoma disease. Here the potential mechanisms of meioticExpand
MDM2-Mediated p21 Proteasomal Degradation Promotes Fluoride Toxicity in Ameloblasts
Results suggest that MDM2-mediated p21 proteasomal degradation with subsequent phospho-p21 attenuation contributes to fluoride-induced apoptosis and may be a potential therapeutic target to mitigate fluoride toxicity. Expand


Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors.
It is shown that p53 activation leads to G1 and G2 phase arrest and can protect cells from mitotic block and apoptosis caused by paclitaxel, and pretreatment with MDM2 antagonists before chemotherapy of tumors with mutant p53 may offer a partial protection to proliferating normal tissues. Expand
Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells.
This work shows how combining a senescence-inducing inhibitor of the mitotic kinase Aurora A (AURKA) with an MDM2 antagonist activates p53 in senescent tumors harboring wild-type 53 and provides a preclinical proof of concept for a combination treatment that leverages both senescences and immune surveillance to therapeutic ends. Expand
Clinical Overview of MDM2/X-Targeted Therapies
Preclinical modeling, which has demonstrated effective in vitro and in vivo killing of WT p53 cancer cells, has now been translated into early clinical trials allowing better assessment of their biological effects and toxicities in patients. Expand
Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development.
RG7112 is the first clinical small-molecule MDM2 inhibitor designed to occupy the p53-binding pocket ofMDM2, which stabilizes p53 and activates the p 53 pathway, leading to cell cycle arrest, apoptosis, and inhibition or regression of human tumor xenografts. Expand
Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy
A novel signaling pathway by which sorafenib exerts its salutary effects in RCC is shown, and the combinations of paclitaxel or doxorubicin with sorafanib show additive cytotoxicity as a function of the VHL status of the cells, suggesting that lower doses of each agent could be used in the clinical setting. Expand
MDM2 antagonist Nutlin-3a protects wild-type p53 cancer cells from paclitaxel
The p53 pathway has an important role in cell cycle arrest and apoptosis. Downregulated levels of p53 have been shown to increase resistance to the cytotoxic effects of chemotherapy or radiotherapy.Expand
Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia.
The findings provide the molecular rationale for concomitant targeting of Aurora kinases and Mdm2 in AML where TP53 mutations are rare and downstream p53 signaling is mostly intact. Expand
Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53
Chemotherapeutics (e.g., aurora kinase inhibitors) designed to target proliferative cells are often nonspecific for tumor cells as normal cycling cells are also susceptible. Indeed, one of the majorExpand
Anti‐mitotic agents: Are they emerging molecules for cancer treatment?☆
This review summarizes the major proteins involved in the mitotic phase that can also be targeted for cancer treatment and addresses the activity of anti‐mitotic drugs tested in clinical trials in recent years. Expand
Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-κB impairs this drug-induced senescence
Results demonstrate that removal of senescent tumour cells by infiltrating myeloid cells is crucial for inhibition of tumour re‐growth and demonstrate that induction of senescence, coupled with immune surveillance, can limit melanoma growth. Expand